Follow
Graham Wheeler
Title
Cited by
Cited by
Year
Adaptive designs in clinical trials: why use them, and how to run and report them
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16, 1-15, 2018
6812018
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial
AL Ahern, GM Wheeler, P Aveyard, EJ Boyland, JCG Halford, AP Mander, ...
The Lancet 389 (10085), 2214-2225, 2017
2372017
How to design a dose-finding study using the continual reassessment method
GM Wheeler, AP Mander, A Bedding, K Brock, V Cornelius, AP Grieve, ...
BMC medical research methodology 19, 1-15, 2019
992019
Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia
C Roddie, J Dias, MA O'Reilly, M Abbasian, A Cadinanos-Garai, ...
Journal of Clinical Oncology 39 (30), 3352-3363, 2021
962021
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs
T Burnett, P Mozgunov, P Pallmann, SS Villar, GM Wheeler, T Jaki
BMC medicine 18, 1-21, 2020
832020
Adaptive designs for dual-agent phase I dose-escalation studies
JA Harrington, GM Wheeler, MJ Sweeting, AP Mander, DI Jodrell
Nature Reviews Clinical Oncology 10 (5), 277-288, 2013
762013
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
A Jayaram, A Wingate, D Wetterskog, G Wheeler, CN Sternberg, R Jones, ...
Annals of Oncology 32 (6), 726-735, 2021
452021
Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis
RC Wilson, P Arkell, A Riezk, M Gilchrist, G Wheeler, W Hope, AH Holmes, ...
Journal of Antimicrobial Chemotherapy 77 (9), 2364-2372, 2022
282022
A review of available software for adaptive clinical trial design
MJ Grayling, GM Wheeler
Clinical Trials 17 (3), 323-331, 2020
272020
Early phase clinical trials extension to guidelines for the content of statistical analysis plans
V Homer, C Yap, S Bond, J Holmes, D Stocken, K Walker, EJ Robinson, ...
bmj 376, 2022
262022
Effectiveness and cost-effectiveness of referral to a commercial open group behavioural weight management programme in adults with overweight and obesity: 5-year follow-up of …
AL Ahern, P Breeze, F Fusco, SJ Sharp, N Islam, GM Wheeler, AJ Hill, ...
The Lancet Public Health 7 (10), e866-e875, 2022
222022
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
GM Wheeler, MJ Sweeting, AP Mander
Statistics in Medicine 36 (16), 2499-2513, 2017
212017
AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials
G Wheeler, M Sweeting, A Mander
PLoS ONE 11 (7), e0159026, 2016
172016
Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
DA Fennell, S Danson, PJ Woll, M Forster, D Talbot, J Child, L Farrelly, ...
Clinical Cancer Research 26 (18), 4748-4755, 2020
152020
Visualising harms in publications of randomised controlled trials: consensus and recommendations
R Phillips, S Cro, G Wheeler, S Bond, TP Morris, S Creanor, C Hewitt, ...
bmj 377, 2022
112022
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
G Wheeler
Statistical Papers, 1-11, 2016
112016
Designing and evaluating dose-escalation studies made easy: the MoDEsT web app
P Pallmann, F Wan, AP Mander, GM Wheeler, C Yap, S Clive, ...
Clinical Trials 17 (2), 147-156, 2020
92020
TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma.
A Davies, B Sage, K Kolluri, D Alrifai, R Graham, B Weil, R Rego, O Bain, ...
Journal of Clinical Oncology 37 (15_suppl), TPS9116-TPS9116, 2019
82019
Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration
GM Wheeler, MJ Sweeting, AP Mander, SM Lee, YKK Cheung
Statistics in medicine 36 (2), 225-241, 2017
82017
ALLCAR19: updated data using AUTO1, a novel fast-off rate CD19 CAR in relapsed/refractory B-cell acute lymphoblastic Leukaemia and other B-cell malignancies
C Roddie, MA O'Reilly, MAV Marzolini, L Wood, J Dias, AC Garai, ...
Blood 136, 3-4, 2020
72020
The system can't perform the operation now. Try again later.
Articles 1–20